Tempo Therapeutics
A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.
$14.5MFunding
ParticipantGS
Gideon Strategic Partners
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
Gideon Strategic Partners is the investment organization named in RADAR and Tempo financing coverage.
Recorded funding activity
RADAR combines RFID and computer vision for item-level retail inventory. Tempo develops injectable microporous scaffolds intended to support tissue regeneration. These records connect two distinct technical products to the same fully named investor.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $184.5M 2 disclosed · full round size, not this investor’s share